Isodiol International Inc. – Delay In Filing Audited Economic Statements – Obtains Management Cease Trade Order from BCSC

[ad_1]

July 30, 2019 – Vancouver, BC –  Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF)
(FSE: LB6B.F)(the “Company” or “Isodiol”), now announces a delay in the filing of its audited
annual monetary statements, connected management’s discussion and evaluation and supporting
officer certificates for the monetary year ended March 31, 2019 (the “Filings”). The Filings are
essential to be produced with the relevant securities regulatory authorities on or ahead of July 29,
2019.

The anticipated delay of its Filings is a outcome of delays in acquiring access to accounting
info pursuant to dispositions of subsidiaries for which the Corporation no longer has
management influence more than.

The Corporation notes that such delays have been resolved and the Corporation is now in the final
stages of the audit and anticipates finishing its Filings ahead of August 16, 2019.

The Corporation has obtained a management cease trade order from the relevant securities
regulators as contemplated by National Policy 12-203 Management Cease Trade Orders of the
Canadian Securities Administrators. The Corporation will comply with the specifications of the
option info recommendations set out in the National Policy. The Corporation is not topic to
any insolvency proceedings.

The Corporation also announces the departure of Kevin Swadish, Chief Income Officer and
Patrick Ogle as a Director and Chief Operating Officer of the Corporation.

Comply with Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/,
on Twitter @Isodiolintlinc, and on Instagram @isodiol.

About Isodiol International Inc.

Isodiol International Inc. is focused on the nutritional overall health positive aspects that are derived from hemp
and is a solution improvement, sales, promoting and distribution enterprise of hemp-primarily based
Customer Packaged Goods (CPG) and options. Isodiol has commercialized a 99%+ pure,
naturally isolated CBD, such as micro-encapsulations, and nano-technologies for good quality
consumable and topical skin care goods. The Corporation received approval for its CBD as an
Active Pharmaceutical Ingredient (API) for use in Completed Pharmaceutical Goods (FPPs), as was
announced on April 26, 2018. Isodiol’s development method incorporates the improvement of more than-thecounter
and pharmaceutical drugs and continued international expansion into Latin America,
Asia, and Europe.

ON BEHALF OF THE BOARD
Marcos Agramont, CEO &amp Director

INVESTOR RELATIONS:
[email protected]
604-409-4409

MEDIA Speak to:
Christopher Hussey
[email protected]

The CSE has not reviewed, authorized or disapproved the content material of this press release.

Forward-Searching Data: This news release includes “forward-hunting information” inside
the which means of applicable securities laws relating to statements with regards to the Company’s
small business, proposed arrangement with creditors, goods and future the Company’s small business, its
solution offerings and plans for sales and promoting. Even though the Corporation believes that the
expectations reflected in the forward-hunting info are affordable, there can be no
assurance that such expectations will prove to be appropriate. Readers are cautioned not to spot
undue reliance on forward-hunting info. Such forward-hunting statements are topic to
dangers and uncertainties that may well result in actual benefits, functionality and developments to differ
materially from these contemplated by these statements based on, amongst other points, the
dangers that the Company’s goods and strategy will differ from these stated in this news release and
the Corporation may well not be capable to carry out its small business plans as anticipated. Except as essential by
law, the Corporation expressly disclaims any obligation and does not intend, to update any forwardlooking
statements or forward-hunting info in this news release. Even though the Corporation
believes that the expectations reflected in the forward-hunting info are affordable, there
can be no assurance that such expectations will prove to be appropriate and tends to make no reference to
profitability primarily based on sales reported. The statements in this news release are produced as of the date
of this release.

The CSE has not reviewed, authorized or disapproved the content material of this press release.



[ad_2]

Latest posts